Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer

Journal of Clinical Oncology

Volumn 20, Issue 24, 2002, Pages 4636-4642

  Du, Xianglin L ^a   Osborne, Cynthia ^a   Goodwin, James S ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT;

ADULT; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COMORBIDITY; DEHYDRATION; DELIRIUM; FATIGUE; FEMALE; FEVER; HEART INFARCTION; HIP FRACTURE; HOSPITALIZATION; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALAISE; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOCYTOPENIA; VOMITING;

AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; COMORBIDITY; DRUG THERAPY; FEMALE; HOSPITALIZATION; HUMANS; MEDICAL RECORD LINKAGE; MEDICARE;

EID: 0037115701     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.05.088     Document Type: Article

References (48)

1. Early Breast Cancer Trialists' Collaborative Group: Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: An overview of 61 randomized trials among 28,896 women. N Engl J Med 319:1681-1692, 1988
2. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:1-15, 71-85, 1992
3. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet 352:930-942, 1998
4. NIH Consensus Conference: Adjuvant chemotherapy for breast cancer. JAMA 254:3461-3463, 1985
5. NIH Consensus Conference: Treatment of early-stage breast cancer. JAMA 265:391-395, 1991
6. The Steering Committee on Clinical Practice: Adjuvant systemic therapy for women with node-negative breast cancer: Guidelines for the care and treatment of breast cancer. Can Med Assoc J 158:S43-S51, 1998 (suppl 3)
7. The Steering Committee on Clinical Practice: Guidelines for the care and treatment of breast cancer: Adjuvant systemic therapy for women with node-positive breast cancer. Can Med Assoc J 158:S52-S64, 1998 (suppl 3)
8. Goldhirsch A, Glick JH, Gelber RD, et al: Meeting highlights: International consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 90:1601-1608, 1998
9. Fisher B: Highlights from recent National Surgical Adjuvant Breast and Bowel Project studies in the treatment and prevention of breast cancer. CA Cancer J Clin 49:159-177, 1999
10. Carlson RW, Anderson BO, Bensinger W, et al: NCCN practice guidelines for breast cancer. Oncology 14:33-49, 2000
11. National Institutes of Health Consensus Development Panel: National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000. J Natl Cancer Inst 93:979-989, 2001
12. Fisher B, Dignam J, Tan-Chiu E, et al: Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes. J Natl Cancer Inst 93:112-120, 2001
13. Hortobagyi GN: Treatment of breast cancer. N Engl J Med 339:974-984, 1998
14. Perry MC, Yarbro JW: Toxicity of Chemotherapy. Orlando, FL, Grune & Stratton, 1984
15. Crivellari D, Bonetti M, Castiglione-Gertsch M, et al: Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: The International Breast Cancer Study Group Trial VII. J Clin Oncol 18:1412-1422, 2000
16. Shapiro CL, Recht A: Drug therapy: Side effects of adjuvant treatment of breast cancer. N Engl J Med 344:1997-2008, 2001
17. Delea TE, Vera-Llonch M, Edelsberg JS, et al: The incidence and cost of hospitalization for 5-FU toxicity among Medicare beneficiaries with metastatic colorectal cancer. Value Health 5:35-43, 2002
18. Earle CC, Tsai JS, Gelber RD, et al: Effectiveness of chemotherapy for advanced lung cancer in the elderly: Instrumental variable and propensity analysis. J Clin Oncol 19:1064-1070, 2001
19. Schrag D, Cramer LD, Bach PB, et al: Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst 93:850-857, 2001
20. Du XL, Goodwin JS: Patterns of use of chemotherapy for breast cancer in older women: Findings from Medicare claims data. J Clin Oncol 19:1455-1461, 2001
21. Du XL, Goodwin JS: Increase of chemotherapy use in older women with breast cancer from 1991 to 1996. Cancer 92:730-737, 2001
22. Potosky AL, Riley GF, Lubitz JD. et al: Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care 31:732-748, 1993
23. Ries LAG, Kosary CL, Hankey BF, et al: SEER Cancer Statistics Review, 1973-1996. Bethesda, MD, National Cancer Institute, 1999, NIH publication 99-2789
24. National Cancer Institute: The SEER Program Code Manual (revised ed). Bethesda, MD, National Cancer Institute, 1994, NIH publication 94-1999
25. Health Care Financing Administration: Data User Reference Guide (DURG). Baltimore, MD, Health Care Financing Administration, January 2000
26. U.S. Public Health Services: International Classification of Diseases, 9th Revision, Clinical Modification (ed 5). Los Angeles, CA, Practice Management Information Corporation, 1996
27. American Medical Association: Physicians' Current Procedural Terminology: CPT 94. Chicago, IL, American Medical Association, 1993
28. Health Care Financing Administration: HCFA Common Procedure Coding System (HCPCS): National Level II Medicare Codes. Los Angeles, CA, Practice Management Information Corporation, 1994
29. Health Care Financing Administration: HCFA Data Dictionary: Revenue Center Codes. Baltimore, MD, Health Care Financing Administration, June 17, 1999
30. Charlson ME, Pompei P, Ales KL, et al: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 40:373-383, 1987
31. Romano PS, Roos LL. Jollis JG: Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: Differing perspectives. J Clin Epidemiol 46:1075-1079, 1993
32. Stokes ME, Davis CS, Koch GG: Categorical Data Analysis Using the SAS System. Cary, NC, SAS Institute, Inc, 1997
33. Samet J, Hunt WC, Key C, et al: Choice of cancer therapy varies with age of patient. JAMA 255:3385-3390, 1986
34. Greenfield S, Blanco DM, Elashoff RM, et al: Patterns of care related to age of breast cancer patients. JAMA 257:2766-2770, 1987
35. Wetle T: Age as a risk factor for inadequate treatment. JAMA 258:516, 1987 (editorial)
36. Goodwin JS, Hunt WC, Humble CG, et al: Cancer treatment protocols: Who gets chosen? Arch Intern Med 148:2258-2260, 1988
37. Muss HB: The role of chemotherapy and adjuvant therapy in the management of breast cancer in older women. Cancer 74:2165-2171, 1994 (7 suppl)
38. Du XL, Freeman JL, Freeman DH, et al: Temporal and regional variation in the use of breast conserving surgery and radiotherapy for older women with early stage breast cancer from 1983 to 1995. J Gerontol Med Sci 54A:474-478, 1999
39. Muss HB: Older age: Not a barrier to cancer treatment. N Engl J Med 345:1127-1128, 2001
40. Begg CB, Cohen JL, Ellerton J: Are the elderly predisposed to toxicity from cancer chemotherapy? An investigation using data from the Eastern Cooperative Oncology Group. Cancer Clin Trials 3:369-374, 1980
41. Gelman RS, Taylor SG IV: Cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: The elimination of age trends in toxicity by using doses based on creatinine clearance. J Clin Oncol 2:1404-1413, 1984
42. Fisher B, Anderson S, Wickerham DL, et al: Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 15:1858-1869, 1997
43. Ibrahim NK, Frye DK, Buzdar AU, et al: Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer: Tolerance and outcome. Arch Intern Med 156:882-888, 1996
44. Christman K, Muss HB, Case LD, et al: Chemotherapy of metastatic breast cancer in the elderly: The Piedmont Oncology Association experience. JAMA 268:57-62, 1992
45. Haskell CM: Cancer Treatment. Philadelphia, PA, WB Saunders, 2001, pp 574-581
46. Ioannidis JP, Lau J: Completeness of safety reporting in randomized trials: An evaluation of 7 medical areas. JAMA 285:437-443, 2001
47. Kessler DA: Introducing MEDWatch: A new approach to reporting medication and device adverse effects and product problems. JAMA 269: 2765-2768, 1993
48. Wu AW: Adverse drug events and near misses: Who's counting? Am J Med 109:166-168, 2000